AD Pipeline Update: First Patient Dosed in Phase 3 Trial of InnoCare Pharma’s TYK2 Inhibitor in China
The first subject has been dosed in the Phase III trial of the InnoCare Pharma’s novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, for the treatment of atopic dermatitis (AD) in China. ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including AD and […]